In The News
WiseTech Global faces class action by shareholders
Cbus dragged to court by ASIC for $20M in claim delays
Noumi privilege ruling could undermine ASIC investigations, Full Court told
Herbert Smith Freehills to merge with US firm Kramer Levin
Honda tells court it should be on the hook for $12M in spat with dealer
Ousted PwC partner settles defamation claim over tax leaks statements
Domestic airfares soared after collapse of regional carrier Rex, ACCC finds
Companies need to report basis for climate change statements, says ASIC
Ex-EY partner accused of tax loss scheme can shield email to general counsel
Judge’s copy and paste decision a ‘canary in a coal mine’, experts say
Please login to bookmarkClose

A new funder is backing a shareholder class action that will be brought against Australian regenerative medicine company Mesoblast over disclosures related to its Remestemcel-L treatment for COVID-19 complications.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au